First experiment study in cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer following neoadjuvant chemohormonotherapy

IF 0.1 Q4 ONCOLOGY Onkourologiya Pub Date : 2021-07-25 DOI:10.17650/1726-9776-2021-17-2-62-68

V. Mager, A. S. Orlov, T. R. Gilmutdinov, A. A. Veshkina, D. Kovalenko, A. V. Zamyatin

{"title":"First experiment study in cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer following neoadjuvant chemohormonotherapy","authors":"V. Mager, A. S. Orlov, T. R. Gilmutdinov, A. A. Veshkina, D. Kovalenko, A. V. Zamyatin","doi":"10.17650/1726-9776-2021-17-2-62-68","DOIUrl":null,"url":null,"abstract":"Background. Nowadays there is no consensus on application of cytoreductive prostatectomy in a complex therapy in patients with oligo-metastatic prostate cancer.Study objective: assessment of short-term results of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer.Materials and methods. Cytoreductive prostatectomy was performed in 7 patients with oligometastatic prostate cancer.Results. Postoperative complications in 3 (42.9 %) out of 7 treated patients were classified as grade IIIb according to Clavien-Dindo scale. Post-surgical analysis of prostate tissue samples showed therapeutic pathomorphism of grade II in 3 patients (42.9 %), grade III in 1 patient (14.3 %) and grade IV in another patient (14.3 %). Urinary continence regained in all the patients. Average postoperative supervision period took 12 months. Disease progression was diagnosed in 1 patient (14.3 %).Conclusion. Combined application of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy can be considered as an alternative method of treatment in a properly selected group of patients with oligo-metastatic prostate cancer.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2021-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2021-17-2-62-68","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background. Nowadays there is no consensus on application of cytoreductive prostatectomy in a complex therapy in patients with oligo-metastatic prostate cancer.Study objective: assessment of short-term results of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy in patients with oligo-metastatic prostate cancer.Materials and methods. Cytoreductive prostatectomy was performed in 7 patients with oligometastatic prostate cancer.Results. Postoperative complications in 3 (42.9 %) out of 7 treated patients were classified as grade IIIb according to Clavien-Dindo scale. Post-surgical analysis of prostate tissue samples showed therapeutic pathomorphism of grade II in 3 patients (42.9 %), grade III in 1 patient (14.3 %) and grade IV in another patient (14.3 %). Urinary continence regained in all the patients. Average postoperative supervision period took 12 months. Disease progression was diagnosed in 1 patient (14.3 %).Conclusion. Combined application of neoadjuvant chemohormonotherapy followed by cytoreductive prostatectomy can be considered as an alternative method of treatment in a properly selected group of patients with oligo-metastatic prostate cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新辅助化疗激素治疗后少转移前列腺癌患者细胞减少性前列腺切除术的首次实验研究

背景。目前，在低转移性前列腺癌患者的综合治疗中，细胞减少性前列腺切除术的应用尚未达成共识。研究目的:评价低转移性前列腺癌患者新辅助激素化疗后减少性前列腺切除术的短期疗效。材料和方法。对7例少转移性前列腺癌行减少性前列腺切除术。7例患者术后并发症3例(42.9%)按照Clavien-Dindo分级为IIIb级。术后前列腺组织样本分析显示治疗性病变3例(42.9%)为II级，1例(14.3%)为III级，1例(14.3%)为IV级。所有患者均出现尿失禁。术后平均监护时间为12个月。1例(14.3%)被诊断为疾病进展。在适当选择的低转移性前列腺癌患者中，联合应用新辅助化疗激素治疗后细胞减少性前列腺切除术可以被认为是一种替代的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Onkourologiya ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

10 weeks

期刊介绍： The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.